Authors:
V.V. ZAKHAROV,P.A. CHERNOUSOV,, K.A. VEKHOVA1A.N. BOGOLEPOVA3
1I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia;
2N.I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow, Russia;
3Federal Center for Brain and Neurotechnology, Federal Medical and Biological Agency of Russia, Moscow, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2024, Vol. 124, No. 4, Issue 2
Abstract:
Arterial hypertension (HTN) is a leading risk factor for cardiovascular disease, including cerebrovascular complications. Damage to the brain as a target organ by hypertension manifests as stroke and/or vascular cognitive impairment (VCI) of varying severity. To identify and assess the severity of VCI, patients with hypertension require a neuropsychological examination, and neuroimaging is required to verify the vascular nature of the disorders. Neuroprotectors, including ethylmethylhydroxypyridine succinate (reference drug – Mexidol), play an important role in the prevention and treatment of VCI, along with antihypertensive therapy. Key words: arterial hypertension, cognitive impairment, cerebrovascular disease, neuroprotection, ethylmethylhydroxypyridine succinate, Mexidol.
